Lv4
676 积分 2025-04-02 加入
Adagrasib-induced photodistributed hyperpigmentation: Two case reports and pathogenetic hypothesis
6天前
已关闭
Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system
6天前
已完结
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting system
6天前
已完结
P3.12.18 Vebreltinib Plus EGFR-TKI in EGFR-Mutated NSCLC With MET Amplification And/Or Overexpression After Failure on EGFR-TKI: A Retrospective Study
1个月前
已关闭
P3.09.07 Local MDT Improve the Survival of Leptomeningeal Metastasis in NSCLC With EGFR Mutation From the CLM-Tree Registry
1个月前
已关闭
EGFR-TKI plus chemotherapy versus tki monotherapy in advanced EGFR-Mutant NSCLC with high PD-L1 expression: a real-world retrospective study
1个月前
已完结
213eTiP First-line oral vinorelbine plus furmonertinib in refractory epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC): A multicenter, non-randomized, two-cohort study
1个月前
已关闭
353eP Furmonertinib in EGFR-mutated NSCLC with or without CNS metastasis: A systematic review and meta-analysis
1个月前
已关闭
Expanding landscape of kinase inhibitor research in 25 years (2001-2025) and advancements of next-generation kinase inhibitors
1个月前
已完结
Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR- mutated non-small cell lung cancer: systematic review and network meta-analysis
2个月前
已完结